AMPH
Price
$25.43
Change
+$0.08 (+0.32%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.17B
38 days until earnings call
Intraday BUY SELL Signals
EBS
Price
$6.33
Change
-$0.03 (-0.47%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
351.74M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs EBS

AMPH vs EBS Comparison Chart in %
View a ticker or compare two or three
VS
AMPH vs. EBS commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a StrongBuy and EBS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
AMPH vs EBS: Fundamental Ratings
AMPH
EBS
OUTLOOK RATING
1..100
7729
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
46
Fair valued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
6997
PRICE GROWTH RATING
1..100
3961
P/E GROWTH RATING
1..100
115
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (46) in the Biotechnology industry is in the same range as AMPH (62) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.

AMPH's Profit vs Risk Rating (90) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.

AMPH's SMR Rating (69) in the Pharmaceuticals Other industry is in the same range as EBS (97) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.

AMPH's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as EBS (61) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (5) in the Biotechnology industry is in the same range as AMPH (11) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHEBS
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (AMPH: $25.35 vs. EBS: $6.37)
Brand notoriety: AMPH and EBS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 122% vs. EBS: 65%
Market capitalization -- AMPH: $1.17B vs. EBS: $351.74M
AMPH [@Pharmaceuticals: Generic] is valued at $1.17B. EBS’s [@Pharmaceuticals: Generic] market capitalization is $351.74M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 1 FA rating(s) are green while EBS’s FA Score has 1 green FA rating(s).

  • AMPH’s FA Score: 1 green, 4 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, both AMPH and EBS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 4 TA indicator(s) are bullish while EBS’s TA Score has 4 bullish TA indicator(s).

  • AMPH’s TA Score: 4 bullish, 4 bearish.
  • EBS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AMPH is a better buy in the short-term than EBS.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а -3.50% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -5.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.75%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

AMPH is expected to report earnings on Nov 09, 2026.

EBS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.75% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
AMPH
Daily Signal:
Gain/Loss:
EBS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CNOB30.340.29
+0.97%
ConnectOne Bancorp
RMCO2.500.02
+0.81%
Royalty Management Holding Corp
SLAB222.510.93
+0.42%
Silicon Laboratories
SAAQ10.060.01
+0.10%
Space Asset Acquisition Corp
CHSCN24.35-0.44
-1.77%
CHS

AMPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMPH has been loosely correlated with AMRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AMPH jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMPH
1D Price
Change %
AMPH100%
-1.78%
AMRX - AMPH
45%
Loosely correlated
-0.35%
IXHL - AMPH
40%
Loosely correlated
+0.31%
EBS - AMPH
37%
Loosely correlated
-3.48%
VTRS - AMPH
36%
Loosely correlated
-1.47%
ZTS - AMPH
36%
Loosely correlated
-1.05%
More

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-3.48%
SIGA - EBS
40%
Loosely correlated
-1.47%
COLL - EBS
40%
Loosely correlated
+0.09%
AMPH - EBS
37%
Loosely correlated
-1.78%
XERS - EBS
33%
Loosely correlated
-3.24%
VTRS - EBS
32%
Poorly correlated
-1.47%
More